Cingulate therapeutics filing

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: SUITE 300: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; KANSAS CITY: … WebCINGULATE THERAPEUTICS LLC. CINGULATE INC. AND. CINGULATE PHARMA LLC. DATED AS OF AUGUST 30, 2024 . ... 2024, which in turn formed Merger Sub by filing …

Form S-8 Cingulate Inc.

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: … WebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … green gluttony seed location https://welcomehomenutrition.com

Cingulate Inc. Reports Fourth Quarter and Full Year 2024

WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... WebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... green goals initiative宣言

SEC FORM D/A

Category:CING Institutional Ownership and Shareholders - Cingulate Inc …

Tags:Cingulate therapeutics filing

Cingulate therapeutics filing

Cingulate Therapeutics Appoints Laurie Myers, PhD, MBA as Chief ...

WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. WebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: …

Cingulate therapeutics filing

Did you know?

WebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here. WebFeb 8, 2024 · Cingulate Therapeutics LLC. February 8, 2024, ... (U.S.) and are instrumental for the filing of the New Drug Application to the U.S. Food and Drug Administration (FDA), expected in the second half ...

WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) … WebJun 29, 2024 · The most recently filed 13Fs

WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... WebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead …

WebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery …

WebCompany profile page for Cingulate Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information green gmc canyonWebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the … green goat cafe clevelandWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … green glue soundproofing australiagreen goat leather strapWebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results … fluted panel wall pricelistWeb1y Target Est. 5.88. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. … green goant rice pilaf nutritionWebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … green goat cafe machynlleth